The present invention relates to amino acid sequences that are directed against IL-23. The amino acid sequences of the present invention comprise two Nanobodies against IL-23 and one Nanobody against serum albumin, linked by two linkers (9GS linkers). In particular, the invention relates to the amino acid sequences of SEQ ID NO: 2 and SEQ ID NO: 3 (listed in Table 1 and FIG. 1) (also referred to herein as “anti-IL 23 polypeptides of the invention”).

The invention provides compositions and methods for treating conditions or diseases associated with expression of a target chimeric antigen receptor (CAR) as described herein. The invention also relates to an anti-target CAR specific to the target CAR as described herein, vectors encoding the same, and recombinant T cells comprising the anti-target CARs of the present invention. The invention also includes methods of administering a genetically modified T cell expressing an anti-target CAR as described herein.

Using protein structural probes one can identify tumor-induced or -produced (TIPS) factors that bind to therapeutic antibodies and change their dynamic structure, thereby negatively affecting their humoral immune functions as well as their pharmacologic activity. Using such protein structural probes and TIPS factors one can screen and identify inhibitors that can counter the binding of TIPS factors to affected therapeutic antibodies. These inhibitors can be used in the presence of a TIPS factor-susceptible antibody (TSA) for treating cancer. An inhibitor can be used alone or in combination with chemotherapy for treating cancer. Patients can be screened to identify those with low or no TIPS factor production as candidates for antibody therapy even in the case in which the antibody is a TSA. Conversely, those with high TIPS factor production are candidates for inhibitor therapy.

The present disclosure relates generally to antibodies and binding fragments thereof that bind to anti-CD123 antibodies, chimeric antigen receptors (CARs), or antibody binding fragments. In particular, the disclosed anti-idiotype antibodies and fragments bind to anti-CD123 antibodies, CARs, or fragments thereof and comprise novel complementary determining regions (CDRs). Finally, the present disclosure relates to methods of using the disclosed antibodies and fragments thereof to expand and/or activate CD123-CAR-expressing immune cells, detecting or quantifying CD123-CARs, and isolating CD123-CAR-expressing immune cells.

The present invention relates to amino acid sequences that are directed against Interleukin-23 (IL-23). The amino acid sequences of the present invention comprise two NANOBODIES® against IL-23 and one NANOBODY® against serum albumin, linked by two linkers (9GS linkers). In particular, the invention relates to the amino acid sequences of SEQ ID NO: 2 and SEQ ID NO: 3 (listed in Table 1 and FIG. 1) (also referred to herein as “anti-IL 23 polypeptides of the invention”).

Compositions, e.g., compositions comprising cellular therapeutics and/or protein therapeutics, and methods of using such compositions for treating cancer are described.

The invention provides methods and kits for qualitatively and/or quantitatively analyzing activation and other properties of activatable antibody therapeutic in biological samples, including tissues and/or biofluid samples. The invention also relates to methods of using a capillary-based immunoassay platform to qualitatively and/or quantitatively analyze levels of activation in biological samples, including tissues and/or biofluid samples.

Provided are compositions and methods that relate to engineering B cells that express heterologous antibodies. The B cells are modified using CRISPR-based approaches. The modified B cells maintain allelic exclusion, and are produced such that endogenous Ig genes are silenced, such as by insertion of a bi-cistronic cDNA into the Igh locus. Functional antibodies are produced by expression of the bi-cistronic cDNA. The modified B cells can be engineered to produce antibodies to any particular epitope. The modified B cells may be administered to an individual who is subsequently vaccinated with a composition comprising the epitope to stimulate production of the antibodies.

Anti-TIGIT antibodies and antigen binding fragments thereof that inhibit TIGIT-mediated signalling are provided, together with combinations comprising said antibodies or antigen binding fragments thereof and methods for their use.

The present invention relates to a first antigen-binding molecule, a second antigen-binding molecule, and a combination thereof. The second antigen-binding molecule binds to an antigen/antigen-binding molecule complex containing a first antigen and the first antigen-binding molecule, and enhances the binding activity of the first antigen-binding molecule to the first antigen.